Second surgery for recurrent ovarian cancer that responds to platinum
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer (the epithelial type).
- Your cancer came back at least 6 months after your last platinum chemotherapy session.
- You have had at least 3 rounds of platinum chemo (maybe with other drugs like Avastin or a PARP inhibitor).
- Doctors have said that a first surgery to remove all visible cancer was not possible.
- You feel well enough to have surgery (ECOG score 0–2).
- Your blood counts, kidney, liver, and nerve function are in a good range for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
This study tests whether removing the recurrent ovarian tumor with surgery, after chemo has worked well, can help women whose cancer came back more than 6 months after their last platinum chemo. It's for a first recurrence only, and the tumor must be able to be completely removed by surgery.
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hear when a new Recurrent Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.